Introduction Baxter 2021 Corporate Responsibility Report 4 2030 Corporate Responsibility Goals Corporate Responsibility Commitment Empower Our Patients Protect Our Planet Appendix Champion Our People and Communities Cross-Cutting Commitments Company Profile Every day, millions of patients, caregivers and health- care providers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For 90 years, we’ve been operating at the intersection where vital innovations that save and sustain lives meet the healthcare providers who make it happen. Our corporate responsibility commitment is fundamental to our ability to deliver on this mission as we grow our business sustainably and strive to meet the needs of all our stakeholders. Baxter provides a broad portfolio of essential healthcare products, including acute and chronic dialysis therapies; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anes- thetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices. On Dec. 13, 2021, Baxter completed its acquisition of Hillrom, a global medical technology leader. Hillrom brings a highly complementary product portfolio and innovation pipeline that will enable Baxter to provide a broader array of medical products and services to patients and clinicians across the care continuum and around the world. Together, we have the ability to transform healthcare by helping to improve patient outcomes, enhancing workflow efficiency and enabling more cost-effective healthcare solutions. Baxter’s combination with Hillrom unlocks the next phase of our transformation journey, presenting a new wave of potential to drive greater impact for patients, healthcare providers, employees, investors and other stakeholders we serve worldwide. Baxter’s heritage and global reach provide a distinct perspective on the needs of patients and caregivers around the world. We have a longstanding commitment to research and development (R&D) and a rich history of medical firsts, from the first commercially manufac - tured IV solutions to the first portable kidney dialysis machine, and many more. Each of our approximately 60,000 employees 1 is dedicated to ensuring that Baxter is there when and where patients need care—from hospitals and clinics to physician offices and homes, in rural areas and major cities around the world. We will continue to transform healthcare by supporting opportunities that will cultivate the next generation of innovators, investing in the pursuit of new discoveries and research, and partnering with world-renowned institutions to further our impact. We underpin this work with a commitment to conduct our business with integrity, attract and develop a more diverse and inclusive workforce, increase operational efficiency and innovate more sustainable products. GLOBAL PRESENCE Baxter (including Hillrom) touches the lives of more than 350 million people every year. As of Dec. 31, 2021, our products, technologies and therapies are available in more than 100 countries across the following geographic segments related to our legacy Baxter business: Americas; Europe, Middle East and Africa (EMEA); Asia Pacific (APAC); and a new global segment for our recently acquired Hillrom business. Our corporate headquarters is located in Deerfield, Illinois, in the United States. R&D is conducted at centers around the the world, including facilities in Belgium, China, Germany, India, Italy, Japan, Sweden and the United States. As of the end of 2021, our products are manufactured in approximately 50 facilities across more than 20 countries. Europe, Middle East and Africa Americas Asia Pacific $ 12.8B 5 2 % 22% Hillrom 2% 24% REVENUE BY SEGMENT, 2021* REVENUE BY PRODUCT CATEGORY, 2021* *Sales and related figures represent fiscal year 2021. Baxter’s full year 2021 financial results include $212 million of Hillrom sales that occurred from the Dec. 13, 2021 acquisition date through Dec. 31, 2021. COMPANY OVERVIEW, 2021 * As of Dec. 31, 2021. ** Approximately 10,000 of those employees joined Baxter in December 2021 as a result of our acquisition of Hillrom. *** This amount does not include Hillrom charitable giving from 2021. *Sales and related figures represent fiscal year 2021. Baxter’s full year 2021 financial results include $212 million of Hillrom sales that occurred from the Dec. 13, 2021 acquisition date through Dec. 31, 2021. 1 00 + Products available in countries* ~6 0 , 000 employees*,** 20 + Manufacturing in countries* $ 52 million in charitable giving *** Renal Care $ 3 . 9 B Pharmaceuticals $ 2. 3 B Advanced Surgery $ 1. 0 B BioPharma Solutions $ 0. 7B Patient Support Systems $ 0. 1B Front Line Care $ 0. 1B Surgical Solutions < $ 0. 1B Acute Therapies $ 0. 8B Medication Delivery $ 2. 9 B Clinical Nutrition $ 1. 0 B Baxter 2021 Corporate Responsibility Report 4